## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.8% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. New DAYBUE STIX Rett Syndrome Formulation Might Change The Case For Investing In ACADIA Pharmaceuticals (ACAD)**
- Source: Simply Wall Street | 20251216T220957 | Somewhat-Bullish | Relevance: 100%
- ACADIA Pharmaceuticals recently received U.S. FDA approval for DAYBUE STIX, a new dye- and preservative-free powder formulation of trofinetide for Rett syndrome, offering more flexible dosing. This approval has led to a higher price target from H.C. Wainwright and supports Acadia's revenue guidance, as the company aims to solidify DAYBUE and NUPLAZID as durable revenue streams. Investors are evaluating whether this new formulation will significantly boost patient retention and long-term upside, particularly given the stock's current valuation projections.

**2. New DAYBUE STIX Rett Syndrome Formulation Might Change The Case For Investing In ACADIA Pharmaceuticals (ACAD)**
- Source: Simply Wall Street | 20251216T200844 | Somewhat-Bullish | Relevance: 100%
- Acadia Pharmaceuticals received FDA approval for DAYBUE STIX, a new dye- and preservative-free powder formulation of trofinetide for Rett syndrome, offering improved flexibility over the existing oral solution. While this could enhance patient retention and supports the Rett franchise, investors should note that the company's near-term earnings primarily rely on NUPLAZID. Analysts like H.C. Wainwright have raised price targets, reflecting optimism about the new formulation's long-term impact on patient retention and Acadia's revenue guidance.

**3. Acadia Pharmaceuticals stock price target raised to $37 by H.C. Wainwright**
- Source: Investing.com India | 20251216T130844 | Bullish | Relevance: 100%
- H.C. Wainwright increased its price target on Acadia Pharmaceuticals (NASDAQ:ACAD) to $37 from $32, maintaining a Buy rating after the launch of DAYBUE STIX, a new powder formulation of the companyâ€™s Rett syndrome drug. This new formulation is expected to improve patient retention and growth, leading to revised penetration assumptions and the higher price target. InvestingPro data suggests ACAD is currently undervalued and possesses strong financials with more cash than debt.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | HC Wainwright & | $37 | $32 | +16% |
| 2025-12-11 | Stifel | $25 | $24 | +4% |
| 2025-12-02 | Mizuho | $29 | $24 | +21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | HC Wainwright & | main | Buy |
| 2025-12-11 | Stifel | main | Hold |
| 2025-12-02 | Mizuho | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($1.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.7% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (8.2%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 3 raises (avg +14%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Analyst sentiment positive (3 raises, avg +14%). Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.5B |
| Beta | 0.67 |
| 52W Range | $13.40 - $27.73 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 32.7 |
| Current P/E | 32.7 |
| YoY Growth | -0.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 7.4% to 3.8% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.2pp (needs >4.0% for momentum thesis). MRS_5 (-1.3%) diverging from MRS_20 - short-term weakness emerging. Outperforming sector by 3.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.76% (CS: 76) | Neutral |
| RSI_14 | 61.3 | Neutral |
| MACD Histogram | -0.04 | Bearish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.126x | Above |
| vs SMA200 | 1.242x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $26.60
- **Stop Loss:** $24.90 (6.4% risk)
- **Target:** $28.30 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 558
- **Position Value:** $14,842.80
- **Portfolio %:** 14.84%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*